<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04892472</url>
  </required_header>
  <id_info>
    <org_study_id>EF- 36</org_study_id>
    <secondary_id>KEYNOTE-B36</secondary_id>
    <nct_id>NCT04892472</nct_id>
  </id_info>
  <brief_title>Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Advanced Non-small Cell Lung Cancer (NSCLC)</brief_title>
  <acronym>KEYNOTE B36</acronym>
  <official_title>EF-36/Keynote B36: A Pilot, Single Arm, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Intrathoracic Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovoCure GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NovoCure Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, single arm, open-label study of Tumor Treating Fields (TTFields) at&#xD;
      150 kHz to the thorax using the NovoTTF-200T System concomitant with IV pembrolizumab in&#xD;
      subjects previously untreated for their advanced or metastatic intrathoracic, PD-L1 positive&#xD;
      non-small cell lung cancer (NSCLC). The primary objective is to evaluate the objective&#xD;
      response rate (ORR) by RECIST 1.1 in subjects with TPS ≥1 percent.&#xD;
&#xD;
      The device is an experimental, portable, battery operated device for chronic administration&#xD;
      of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor,&#xD;
      by means of surface, insulated electrode arrays.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TTFields have demonstrated significant activity in in-vitro and NSCLC pre-clinical models,&#xD;
      both as a single modality treatment and in combination with chemotherapies and PD-1&#xD;
      inhibitors. With taxanes, TTFields have been demonstrated to act synergistically, while&#xD;
      TTFields have been shown to be additive when combined with PD-1 inhibition.&#xD;
&#xD;
      In a pilot study of 42 patients with advanced NSCLC who had tumor progression after at least&#xD;
      one line of prior chemotherapy, all participants received pemetrexed together with TTFields&#xD;
      (150 kHz) applied to the chest and upper abdomen until disease progression. The combination&#xD;
      was well tolerated and the only device-related adverse event was mild to moderate contact&#xD;
      dermatitis. Efficacy endpoints were remarkably high compared to historical data for&#xD;
      pemetrexed alone.&#xD;
&#xD;
      The potency of TTFields combined with checkpoint inhibition has been investigated in&#xD;
      pre-clinical models. In an in-vivo experiment, C57Bl/6 mice were injected directly into the&#xD;
      lungs with LLC-1 cells. Application of TTFields to the mouse lungs was maintained for 7 days&#xD;
      and parallel to the ongoing I.P. injection of anti-PD-1. The combined treatment of TTFields&#xD;
      and anti-PD-1 led to a significant decrease in tumor volume as compared to control mice and&#xD;
      to mice treated with anti-PD-1 alone. The combined treatment also resulted in an increase in&#xD;
      the percentage of tumor-infiltrating leukocytes (CD45+). Specifically there was a&#xD;
      significantly higher frequency of macrophages (CD45+/CD11b+/F4/80+) and DCs (CD45+/CD11c+) in&#xD;
      tumors from mice that were concomitantly treated with TTFields and anti-PD-1. The PD-L1&#xD;
      expression levels of these cells were increased as compared to the control group suggesting&#xD;
      an adaptive immune attempt to limit the inflammatory response elicited by the combined&#xD;
      treatment. Compatibly, cytotoxic T-cells isolated from tumors treated with TTFields and&#xD;
      anti-PD-1 demonstrated increased production of IFN-γ. 061&#xD;
&#xD;
      Taken together, these results suggest that the combination of TTFields and anti-PD-1&#xD;
      augmented the immune response resulting in improved tumor control.&#xD;
&#xD;
      The study will enroll 66 patients, whose tumors are classified as TPS&gt;1% and in whom EGFR or&#xD;
      ALK-directed therapy is not indicated, are projected to be enrolled in this study for&#xD;
      examination of the effectiveness and safety of TTFields concomitant with pembrolizumab.&#xD;
&#xD;
      In addition, all patients must meet all eligibility criteria.&#xD;
&#xD;
      Subjects will be enrolled after a Screening Phase of up to 28 days to receive TTFields at 150&#xD;
      kHz to the thorax using the NovoTTF-200T System for at least 18 hours a day on average&#xD;
      concomitant with pembrolizumab 200 mg IV every 3 weeks. Each subject will participate in the&#xD;
      study for approximately 2 years from the time the subject signs the Informed Consent Form&#xD;
      (ICF) through the final contact.&#xD;
&#xD;
      Treatment with TTFields and pembrolizumab will continue for 24 months (TTFields) and until&#xD;
      either (1) 35 study treatments have been administered (pembrolizumab), (2) there is&#xD;
      documented disease progression (per iRECIST criteria), (3) unacceptable adverse event(s), (4)&#xD;
      intercurrent illness that prevents further administration of treatment, (5) investigator's&#xD;
      decision to withdraw the subject, (6) subject withdraws consent, (7) pregnancy of the&#xD;
      subject, (8) non-compliance with study treatment or procedure requirements, or (9)&#xD;
      administrative/Sponsor decisions.&#xD;
&#xD;
      In case of discontinuation of either of the study treatments due to reasons other than&#xD;
      disease progression, the remaining treatment should continue until disease progression or 24&#xD;
      months (TTFields) / 35 cycles (pembrolizumab).&#xD;
&#xD;
      If an alternative anticancer therapy is initiated, the patient will be removed from the&#xD;
      study.&#xD;
&#xD;
      Subjects who discontinue all study treatments prior to disease progression will be monitored&#xD;
      for disease status in the Observation Phase until (1) disease progression is confirmed by the&#xD;
      site, (2) a non-study cancer treatment is initiated, (3) consent is withdrawn, or (4) the&#xD;
      subject is lost to follow-up. Subjects will have post-treatment monthly follow-up by&#xD;
      telephone for disease status until death, withdrawing consent, becoming lost to follow-up, or&#xD;
      end of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2021</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>24 months</time_frame>
    <description>ORR will be measured from the date of enrollment to date of progression (in months) based on RECIST 1.1 criteria. The analysis will include patients with PD-L1 expression TPS≥1-49 percent and TPS≥50 percent as a Secondary Outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>Survival will be measured from date of enrollment until date of death. The analysis will include patients with PD-L1 expression TPS≥1-49 percent and TPS≥50 percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>The analysis will be estimated proportions of patients who are progression-free based on the RECIST 1.1 criteria following the time of enrollment. The analysis will include patients with PD-L1 expression TPS≥1-49 percent and TPS≥50 percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival at 6 months (PFS6)</measure>
    <time_frame>6 months</time_frame>
    <description>The analysis will be estimated proportions of patients who are progression-free at 6 months based on the RECIST 1.1 criteria following the time of enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year survival rates</measure>
    <time_frame>12 months</time_frame>
    <description>The analyses will be performed based on estimated proportions of patients who are alive at one year following enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>24 months</time_frame>
    <description>The analysis will be defined as the time from response to progression/death (P/D) based on RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>24 months</time_frame>
    <description>Will be defined as the percentage of patients with advanced or metastatic cancer who have achieved complete response (CR), partial response (PR), and stable disease (SD) by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability: adverse events (AEs)</measure>
    <time_frame>24 months</time_frame>
    <description>Will be defined as the incidence, frequency and severity of adverse events (AEs) noted in patients treated with TTFields concomitant with pembrolizumab, as well as their association with study treatments</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Study Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab and TTFields</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NovoTTF-200T</intervention_name>
    <description>All patients enrolled in the study will receive TTFields treatment, delivered for at least 18 hours a day on average using NovoTTF-200T together with pembrolizumab, a standard immunotherapy agent, which is delivered intravenously.</description>
    <arm_group_label>Study Arm</arm_group_label>
    <other_name>Drug: Pembrolizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed, newly diagnosed unresectable stage III or&#xD;
             metastatic (M1a) intrathoracic NSCLC without EGFR sensitizing mutation or ALK&#xD;
             translocation&#xD;
&#xD;
          -  Age ≥ 22 years&#xD;
&#xD;
          -  Have a PD-L1 positive (TPS≥1%) tumor by local laboratory assessment&#xD;
&#xD;
          -  Measurable disease by RECIST 1.1&#xD;
&#xD;
          -  ECOG performance status of 0 to 1&#xD;
&#xD;
          -  Have not received prior systemic treatments for NSCLC.&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Able to operate the NovoTTF-200T system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has an extrathoracic metastasis (i.e. M component is M1b or M1c)&#xD;
&#xD;
          -  Has an EGFR sensitizing mutation and/ or ALK translocation&#xD;
&#xD;
          -  If Stage III, can be treated with curative intent with either surgical resection&#xD;
             and/or chemoradiation&#xD;
&#xD;
          -  Has received prior systemic anti-cancer therapy or prior radiotherapy for NSCLC&#xD;
             (palliative radiotherapy is allowed)&#xD;
&#xD;
          -  Being unable to operate the NovoTTF-200T device independently or with the help of a&#xD;
             caregiver&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Significant illnesses not associated with the primary disease&#xD;
&#xD;
          -  Implanted electronic devices (e.g. pacemaker) in the upper torso&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cabilia Pichardo, MD</last_name>
    <phone>+1 603-436-2809</phone>
    <email>clinicaltrials@novocure.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Care of North Florida</name>
      <address>
        <city>Lake City</city>
        <state>Florida</state>
        <zip>32024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Endsley</last_name>
      <phone>386-755-1655</phone>
      <email>jendsley@ccofnf.com</email>
    </contact>
    <investigator>
      <last_name>Waseemulla Khan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AdventHealth Orlando Research Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejandra Ricaurte</last_name>
      <phone>407-303-7456</phone>
      <email>alejandra.ricaurte@adventhealth.com</email>
    </contact>
    <investigator>
      <last_name>Tarek Mekhail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Maine Medical Center</name>
      <address>
        <city>Lewiston</city>
        <state>Maine</state>
        <zip>04240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Chase</last_name>
      <phone>207-782-9835</phone>
      <email>chaseje@cmhc.org</email>
    </contact>
    <investigator>
      <last_name>Milaim Mustafa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OptumCare Cancer Care</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Martinez</last_name>
      <phone>702-724-8787</phone>
      <email>christine.martinez@optum.com</email>
    </contact>
    <investigator>
      <last_name>John Ellerton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arnot Ogen Medical Center - Falck Cancer Center</name>
      <address>
        <city>Elmira</city>
        <state>New York</state>
        <zip>14905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy Rumsey</last_name>
      <phone>607-271-3796</phone>
      <email>crumsey@arnothealth.org</email>
    </contact>
    <investigator>
      <last_name>Serge Dauphin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Specialists of Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joe Howe</last_name>
      <phone>704-247-9179</phone>
      <phone_ext>201</phone_ext>
      <email>joe.howe@djlresearch.com</email>
    </contact>
    <investigator>
      <last_name>Justin Favaro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Cancer Specialists</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristi Simcox</last_name>
      <phone>865-934-2670</phone>
      <email>kristi.simcox@biomed-research.com</email>
    </contact>
    <investigator>
      <last_name>Richard T Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novocuretrial.com/</url>
    <description>Novocure Clinical Trial Website</description>
  </link>
  <reference>
    <citation>Lee SX, Wong ET, Swanson KD. Mitosis Interference of Cancer Cells by NovoTTF-100A Causes Decreased Cellular Viability. Cancer Res. 2013;73; 709. http://cancerres.aacrjournals.org/content/73/8%7B_%7DSupplement/709.abstract.</citation>
  </reference>
  <reference>
    <citation>Bomzon Z, Urman N, Wenger C, et al. Transducer array layout optimization for treating lung-based tumors with TTFields. J Clin Oncol. 2015;33(suppl; abstr e18503). http://meetinglibrary.asco.org/content/147908-156.</citation>
  </reference>
  <reference>
    <citation>Pless M, Droege C, von Moos R, Salzberg M, Betticher D. A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer. Lung Cancer. 2013;81(3):445-450. doi:10.1016/j.lungcan.2013.06.025 17. Hanna N, Shepherd FA, Fossella F V, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589-1597. doi:10.1200/JCO.2004.08.163</citation>
  </reference>
  <results_reference>
    <citation>Kirson ED, Dbalý V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Gurvich Z, Schneiderman R, Wasserman Y, Salzberg M, Ryffel B, Goldsher D, Dekel E, Palti Y. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10152-7. Epub 2007 Jun 5.</citation>
    <PMID>17551011</PMID>
  </results_reference>
  <results_reference>
    <citation>Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, Schatzberger R, Palti Y. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004 May 1;64(9):3288-95.</citation>
    <PMID>15126372</PMID>
  </results_reference>
  <results_reference>
    <citation>Giladi M, Schneiderman RS, Voloshin T, Porat Y, Munster M, Blat R, Sherbo S, Bomzon Z, Urman N, Itzhaki A, Cahal S, Shteingauz A, Chaudhry A, Kirson ED, Weinberg U, Palti Y. Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells. Sci Rep. 2015 Dec 11;5:18046. doi: 10.1038/srep18046.</citation>
    <PMID>26658786</PMID>
  </results_reference>
  <results_reference>
    <citation>Pless M, Weinberg U. Tumor treating fields: concept, evidence and future. Expert Opin Investig Drugs. 2011 Aug;20(8):1099-106. doi: 10.1517/13543784.2011.583236. Epub 2011 May 9. Review.</citation>
    <PMID>21548832</PMID>
  </results_reference>
  <results_reference>
    <citation>Mun EJ, Babiker HM, Weinberg U, Kirson ED, Von Hoff DD. Tumor-Treating Fields: A Fourth Modality in Cancer Treatment. Clin Cancer Res. 2018 Jan 15;24(2):266-275. doi: 10.1158/1078-0432.CCR-17-1117. Epub 2017 Aug 1. Review.</citation>
    <PMID>28765323</PMID>
  </results_reference>
  <results_reference>
    <citation>Giladi M, Weinberg U, Schneiderman RS, Porat Y, Munster M, Voloshin T, Blatt R, Cahal S, Itzhaki A, Onn A, Kirson ED, Palti Y. Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo. Semin Oncol. 2014 Oct;41 Suppl 6:S35-41. doi: 10.1053/j.seminoncol.2014.09.006. Epub 2014 Sep 8.</citation>
    <PMID>25213867</PMID>
  </results_reference>
  <results_reference>
    <citation>Voloshin T, Kaynan N, Davidi S, Porat Y, Shteingauz A, Schneiderman RS, Zeevi E, Munster M, Blat R, Tempel Brami C, Cahal S, Itzhaki A, Giladi M, Kirson ED, Weinberg U, Kinzel A, Palti Y. Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. Cancer Immunol Immunother. 2020 Jul;69(7):1191-1204. doi: 10.1007/s00262-020-02534-7. Epub 2020 Mar 6.</citation>
    <PMID>32144446</PMID>
  </results_reference>
  <results_reference>
    <citation>Kirson ED, Giladi M, Gurvich Z, Itzhaki A, Mordechovich D, Schneiderman RS, Wasserman Y, Ryffel B, Goldsher D, Palti Y. Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs. Clin Exp Metastasis. 2009;26(7):633-40. doi: 10.1007/s10585-009-9262-y. Epub 2009 Apr 23.</citation>
    <PMID>19387848</PMID>
  </results_reference>
  <results_reference>
    <citation>Bomzon Z, Urman N, Wenger C, Giladi M, Weinberg U, Wasserman Y, Kirson ED, Miranda PC, Palti Y. Modelling Tumor Treating Fields for the treatment of lung-based tumors. Annu Int Conf IEEE Eng Med Biol Soc. 2015;2015:6888-91. doi: 10.1109/EMBC.2015.7319976.</citation>
    <PMID>26737876</PMID>
  </results_reference>
  <results_reference>
    <citation>Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbalý V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012 Sep;48(14):2192-202. doi: 10.1016/j.ejca.2012.04.011. Epub 2012 May 18.</citation>
    <PMID>22608262</PMID>
  </results_reference>
  <results_reference>
    <citation>Kirson ED, Schneiderman RS, Dbalý V, Tovarys F, Vymazal J, Itzhaki A, Mordechovich D, Gurvich Z, Shmueli E, Goldsher D, Wasserman Y, Palti Y. Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med Phys. 2009 Jan 8;9:1. doi: 10.1186/1756-6649-9-1.</citation>
    <PMID>19133110</PMID>
  </results_reference>
  <results_reference>
    <citation>Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017 Dec 19;318(23):2306-2316. doi: 10.1001/jama.2017.18718. Erratum in: JAMA. 2018 May 1;319(17):1824.</citation>
    <PMID>29260225</PMID>
  </results_reference>
  <results_reference>
    <citation>Taphoorn MJB, Dirven L, Kanner AA, Lavy-Shahaf G, Weinberg U, Taillibert S, Toms SA, Honnorat J, Chen TC, Sroubek J, David C, Idbaih A, Easaw JC, Kim CY, Bruna J, Hottinger AF, Kew Y, Roth P, Desai R, Villano JL, Kirson ED, Ram Z, Stupp R. Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018 Apr 1;4(4):495-504. doi: 10.1001/jamaoncol.2017.5082.</citation>
    <PMID>29392280</PMID>
  </results_reference>
  <results_reference>
    <citation>Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003 Jul 15;21(14):2636-44.</citation>
    <PMID>12860938</PMID>
  </results_reference>
  <results_reference>
    <citation>Ceresoli GL, Aerts JG, Dziadziuszko R, Ramlau R, Cedres S, van Meerbeeck JP, Mencoboni M, Planchard D, Chella A, Crinò L, Krzakowski M, Rüssel J, Maconi A, Gianoncelli L, Grosso F. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. Lancet Oncol. 2019 Dec;20(12):1702-1709. doi: 10.1016/S1470-2045(19)30532-7. Epub 2019 Oct 15. Erratum in: Lancet Oncol. 2020 Feb;21(2):e70.</citation>
    <PMID>31628016</PMID>
  </results_reference>
  <results_reference>
    <citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313.</citation>
    <PMID>30207593</PMID>
  </results_reference>
  <results_reference>
    <citation>Toms SA, Kim CY, Nicholas G, Ram Z. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. J Neurooncol. 2019 Jan;141(2):467-473. doi: 10.1007/s11060-018-03057-z. Epub 2018 Dec 1.</citation>
    <PMID>30506499</PMID>
  </results_reference>
  <results_reference>
    <citation>Mrugala MM, Engelhard HH, Dinh Tran D, Kew Y, Cavaliere R, Villano JL, Annenelie Bota D, Rudnick J, Love Sumrall A, Zhu JJ, Butowski N. Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe). Semin Oncol. 2014 Oct;41 Suppl 6:S4-S13. doi: 10.1053/j.seminoncol.2014.09.010. Epub 2014 Sep 16. Erratum in: Semin Oncol. 2015 Jun;42(3):e33-43.</citation>
    <PMID>25213869</PMID>
  </results_reference>
  <results_reference>
    <citation>Kanner AA, Wong ET, Villano JL, Ram Z; EF-11 Investigators. Post Hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A™ system versus best physician's choice chemotherapy. Semin Oncol. 2014 Oct;41 Suppl 6:S25-34. doi: 10.1053/j.seminoncol.2014.09.008. Epub 2014 Sep 16. Erratum in: Semin Oncol. 2015 Jun;42(3):e56-66.</citation>
    <PMID>25213871</PMID>
  </results_reference>
  <results_reference>
    <citation>Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EGE; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2. Review. Erratum in: Lancet Oncol. 2019 May;20(5):e242.</citation>
    <PMID>28271869</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 13, 2021</study_first_submitted>
  <study_first_submitted_qc>May 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Advanced non-small cell lung cancer</keyword>
  <keyword>Metastatic non-small cell lung cancer</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>PDL-1 positive</keyword>
  <keyword>Treatment</keyword>
  <keyword>Minimal toxicity</keyword>
  <keyword>TTFields</keyword>
  <keyword>Tumor Treating Fields</keyword>
  <keyword>Novocure</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Merck</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

